LC
PRDS

Littlejohn & Co’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Littlejohn & Co’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-72,925
Closed -$726K – 201
2021
Q3 		$726K Sell
72,925
-5,000
-6% -$49.7K 0.21% 47
2021
Q2 		$779K Buy
+77,925
New +$782K 0.23% 48

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Littlejohn & Co's PRDS Position: Q4 2021 in Review

Littlejohn & Co sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2021, closing a stake of 72,925 shares — an estimated $726K sold.

Littlejohn & Co first reported a position in PRDS in Q2 2021 and held it in 2 quarters. The position peaked at $779K in Q2 2021. 41 funds tracked by Wall St. Rank hold PRDS as of Q4 2021.

  • Littlejohn & Co reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Littlejohn & Co sold 72,925 Pardes Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $726K.
  • Littlejohn & Co first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Littlejohn & Co's Pardes Biosciences, Inc. Common Stock position peaked at $779K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2021.

Based on Littlejohn & Co's 13F filing for Q4 2021, filed 11 Feb 2022.